Shares of Stoke Therapeutics, Inc. ( NASDAQ:STOK – Get Free Report ) have been assigned a consensus recommendation of 'Moderate Buy' from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $23.50. STOK has been the topic of a number of research reports.

https://www.dailypolitical.com/2023/08/27/stoke-therapeutics-inc-nasdaqstok-receives-23-50-consensus-target-price-from-analysts.html

#dailypolitical